Procaps Group S.A. (PROC) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Procaps Group S.A. (PROC:NASDAQ), powered by AI.

Current Price
$0.03
P/E Ratio
0.1
Market Cap
3M
Sector
Healthcare
What is the Procaps Group S.A. stock price forecast?

Procaps Group S.A. is currently trading at $0.03. View real-time AI analysis on Alpha Lenz.

What is Procaps Group S.A. insider trading activity?

View the latest insider trading data for Procaps Group S.A. on Alpha Lenz.

What is Procaps Group S.A.'s P/E ratio?

Procaps Group S.A.'s P/E ratio is 0.1.

Procaps Group S.A.

NASDAQ · PROC
$0.03+0.00(+0.00%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Procaps Group S.A.'s future dividend policy...
Alpha Chat Insight

Procaps Group S.A. trades at a P/E of 0.1 (undervalued) with modest ROE of -221.9%.

Ask for details

Company Overview

Procaps Group S.A. is a leading pharmaceutical company specializing in the development, manufacturing, and commercialization of pharmaceutical and nutritional products. The company is recognized for its innovation in the softgel and related technologies, which are critical for creating advanced dosage forms and drug delivery systems. With an emphasis on improving health outcomes, Procaps Group serves a diverse range of sectors, including prescription medications, over-the-counter products, and a variety of nutritional supplements. One of the key features of Procaps Group is its commitment to research and development, which has positioned it as a pioneer in the Latin American pharmaceutical industry. Operating with a global footprint, the company supplies its products to more than 50 countries worldwide, impacting industries such as healthcare, wellness, and nutrition. Procaps Group S.A. holds a significant place in the pharmaceutical market due to its focus on technological advancements and its ability to meet global health demands through strategic partnerships and supply chain efficiencies. Its role is particularly vital in supporting disease prevention and management through its wide array of innovative health solutions.

CEOMr. Ruben Minski
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees5,500

Company Statistics

FY 2022

Profile

$2.54MMarket Cap
$409.92MRevenue
0.00Shares Out
5,500Employees

Margins

58.44%Gross
10.89%EBITDA
9.51%Operating
12.86%Pre-Tax
10.38%Net

Valuation

0.06P/E
-2.70P/B
0.01EV/Sales
5.48EV/EBITDA
-0.15P/FCF

Growth (CAGR)

8.07%Rev 3Yr
N/ARev 5Yr
2.68%Op Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

9.22%ROA
-221.90%ROE
17.02%ROIC

Financial Health

$43.00MCash & Cash Equivalents
$419.06MNet Debt
-24604.10%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Procaps Group S.A. (ticker: PROC) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 5,500 employees. Market cap is $3M.

The current price is $0.025 with a P/E ratio of 0.06x and P/B of -2.7x.

ROE is -221.90% and operating margin is 9.51%. Annual revenue is $410M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Procaps Group S.A. (PROC) Stock Forecast 2026 $0.03 — Price, Financials & Analyst Targets | Alpha Lenz